Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 5/20 | 0.49 |
| ▸ | CCR1 | P32246 | 4/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.45 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4977320 | 0.91 | CCR3 (0.43) | CCR3CCR1SIGMAR1DRD4MCHR1 | |
| SCHEMBL4199788 | 0.86 | SIGMAR1 (0.57) | CCR3CCR1SIGMAR1DRD4MCHR1 | |
| SCHEMBL21088709 | 0.73 | CXCR3 (0.53) | DRD4 | |
| SCHEMBL4196970 | 0.72 | HSD17B10 (0.44) | — | |
| SCHEMBL4213140 | 0.72 | APEX1 (0.40) | — | |
| SCHEMBL4221350 | 0.72 | CCR3 (0.43) | CCR3SIGMAR1DRD4MCHR1 | |
| SCHEMBL12011091 | 0.71 | KDM4E (0.57) | SIGMAR1DRD4MCHR1 | |
| SCHEMBL4433119 | 0.69 | CCR2 (0.55) | SIGMAR1DRD4TEAD1CCR2 | |
| SCHEMBL29725664 | 0.69 | CCR2 (0.55) | SIGMAR1DRD4TEAD1CCR2 | |
| SCHEMBL29725714 | 0.69 | CCR2 (0.55) | SIGMAR1DRD4TEAD1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1994002-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007102767-A1 | PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ASTRAZENECA AB (SE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023733-A1 | Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them | CCR3, CCR1, CCR5 | CCR3 1/4885CCR1 2/4885SIGMAR1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.